• Seeding is a common cause of retinoblastoma relapse.
Introduction
Salvage of retinoblastoma eyes has historically been limited by the presence of seeds, which consist of small tumor foci in the vitreous and subretinal space that can result in multiple new tumors, tumor relapse, and subsequent loss of the eye [1] [2] [3] . The advent of a safe and efficacious method for delivering intravitreal injection of melphalan (IVM) has revolutionized the current approach for treating seeding in advanced retinoblastoma [4] . Previous reports on the efficacy of intravitreal melphalan demonstrate 100% success in eradicating vitreous seeding and high globe salvage rates of 68-86% on par with rates previously attained with external beam radiation therapy [5] [6] [7] [8] [9] [10] .
While success rates are encouraging, the exact timing, dosage, and number of injections is still under review. Currently, no "gold standard" of care has been defined for intravitreal chemotherapy in the same way that norms exist for systemic and intra-arterial chemotherapy. One hypothesis is to combine therapy and initiate concurrent IVM with cycles 4-6 of systemic chemotherapy. This approach has the potential benefit of providing synergistic antineoplastic effects against vitreous seeds while decreasing the overall number of examinations under anesthesia (EUA) that these children experience, given that IVM after systemic chemoreduction often requires 3 or more weekly injections [5, 6] .
In this case series, we examine the results of 6 patients diagnosed with advanced retinoblastoma with persistent vitreous seeding during chemoreduction who were treated with concurrent IVM injections with the last 3 cycles of systemic chemoreduction. The main outcome measure was event-free globe survival. The secondary objective was to compare the efficacy and toxicity to previous studies wherein IVM was initiated after systemic chemoreduction (e.g., sequential therapy).
Methods
We conducted a retrospective chart review of patients diagnosed with retinoblastoma at the Children's Hospital Los Angeles (CHLA) from 2014 to 2017. Patients who received concurrent intravitreal melphalan and systemic chemoreduction for persistent seeding were included. The Institutional Review Board approved this study.
The treatment protocol for retinoblastoma at CHLA has previously been published [11, 12] . The injection procedure closely adheres to the protocol outlined by Munier and colleagues [13] [14] [15] and previously published [6] . Although a standardized dosage of melphalan has not been fully established due to the relative novelty of the treatment modality, previous publications support the usage of 20-40 µg. After Francis et al.'s [16] report of electroretinogram amplitude decrease after 30 µg of melphalan, IVM dosing was limited to maximally 30 µg; at our center, 25 µg is the most frequently used dose with modifications made for the clinical burden of seeding.
For the concurrent IVM injection protocol, follow-up EUA and injection were performed at 4-week intervals on the same day as administration of systemic chemoreduction. This protocol was utilized for patients with persistently active vitreous seeding diagnosed after 3 cycles of systemic chemotherapy, with patients receiving IVM on the same day as the 4th, 5th, and 6th cycles of chemoreduction. For persistent or recurrent seeding diagnosed after the completion of systemic chemoreduction, another series of weekly injections was performed following the previously described protocol [5, 6] . One patient received 5 total injections within cycles 4-6 of chemotherapy.
Eyes were classified according to the International Intraocular Retinoblastoma Classification (IIRC) System outlined by Linn Murphree [17] and the seeding classification outlined by Munier [14] and Francis et al. [7, 18] .
A retrospective chart review was completed to obtain age at diagnosis, gender, laterality, genetic testing status, length of follow-up, dose and number of intravitreal injections, and clinical response to injection.
Results
Demographic and management details of each case are provided in Table 1 . Comparisons to the larger previously published cohort, which included 28 eyes receiving systemic chemotherapy and IVM [5] , are displayed in Table 2 by seed class [7, 14] . In this group of 28 eyes, 6 eyes demonstrated persistent seeding during systemic chemotherapy. In the current study, all 6 eyes of 6 patients included underwent attempted salvage therapy with concurrent systemic chemoreduction and IVM due to persistent vitreous seeding. A median melphalan dose of 25 µg and a median of 3 injections were required similar to the larger cohort of patients. The mean cumulative dose of melphalan was just over 100 µg in both groups as well. The median age was slightly older in the concurrent therapy group, and the rate of toxicity was greater. Spherical seeding was only seen in the larger cohort, as this type of seed morphology is described primarily in recurrent cases. Two of 6 eyes required additional IVM therapy after the 3 injections given during chemotherapy. 100% of eyes showed complete resolution of seeding; however, all eyes also demonstrated some level of toxicity. Three eyes developed grade 3 retinal toxicity, and 1 eye developed grade 4 retinal toxicity. Two eyes developed both a cataract and iris atrophy. Four of the 6 eyes were salvaged. 
Discussion
This case series reports the outcomes of a small cohort of patients with retinoblastoma at CHLA treated with systemic intravenous chemoreduction and concurrent IVM for persistently active vitreous seeding. Overall, treatment with systemic intravenous chemotherapy, local consolidation, and concurrent IVM resulted in a globe salvage rate of 67% (4 of 6 eyes) at 11.5 months' median follow-up (range 6-29 months). No eyes were enucleated due to progressive vitreous seeding; IVM was 100% successful in treating vitreous seeding and avoidance of external beam radiation therapy.
A previous series examining all eyes treated with IVM for persistent or recurrent vitreous seeding demonstrated a salvage rate of 68% with 100% success of the IVM therapy in eradicating vitreous seeds [5] . The 67% salvage rate of this case series suggests that concurrent chemotherapy and IVM may be a viable treatment option for patients with persistent seeding. However, there did not seem to be an advantage to concurrent IVM when considering globe salvage rates alone.
A clear benefit to this approach is reduced need for multiple weekly examinations under anesthesia at the end of chemoreduction for additional IVM, although 1 of the cases did require 7 additional injections. All patients in this series received concurrent IVM injections during their already scheduled EUA along with chemotherapy cycles 4-6. Considering the young age of the patients undergoing IVM (median age 25 months, SD 5.6), the reduction of additional anesthesia sessions is an advantage for this patient population [19] . There were no cases of extraocular tumor spread when performing IVM prior to the completion of systemic chemotherapy for advanced retinoblastoma.
Retinal toxicity was determined based on the system delineated by Munier [14] and classified as grade 1-5. In this case series, 3 of 6 eyes developed grade 3 posterior retinal toxicity described as salt-and-pepper retinal pigment epithelial (RPE) changes extending posterior to the equator but sparing the macula. One eye developed grade 4 retinopathy involving the macula. No eye developed grade 5 retinopathy. IVM-related anterior toxicities occurred in 2 of 6 eyes after injection (neither eye had retinal toxicity). In both these eyes, combined cataract and iris atrophy occurred. In comparison, previous data from our center reported grade 3 or higher retinal toxicity and/or anterior segment toxicity, including cataract, focal iris atrophy, and transient anterior segment inflammation developing in about 43% of patients [5, 6] . Our data from this small case series reflect higher rates of toxicity than previously demonstrated by our center, which examined all patients who received IVM with systemic chemoreduction. This increased toxicity could be attributed to the fact that IVM and systemic chemoreduction were administered concurrently to the posterior segment at therapeutic doses. Another possibility includes the advanced presentation of these patients with persistent seeding that did not respond to chemotherapy alone, which necessitated earlier intervention of melphalan and concurrent therapy and, therefore, made them potentially more prone to developing higher rates of toxicity regardless of management.
It is important to note that unlike intra-arterial chemotherapy [20] , systemic chemotherapy alone has not been associated with retinal toxicity [21] . Intravitreal delivery of chemotherapy is not without its own set of side effects, including retinal toxicity as described by Munier [14] . Suzuki et al. [22] reported findings for anterior toxicity, including iris atrophy and dense cataracts, in 8.7% of eyes (23/264) and diffuse chorioretinal atrophy in 0.8% of eyes (2/264). Ghassemi and Shields [23] reported RPE changes, cataracts, and phthisis in 25% of eyes (3/12). Munier et al. [24] described a localized retinal toxicity rate of 43% (10/26 eyes), and Tuncer et al. [8] reported a rate of 39% (2/7) for RPE mottling at the site of injections. A recent study by Kiratli et al. [25] reported vitreous hemorrhage in 18% of injected eyes (7/39) and "widespread" RPE changes in 8% of eyes (3/39). While the grading system proposed by Munier [14] was not used in this (and other) studies, "widespread" likely indicates at least greater than grade 3. It has been suggested that doses > 30 µg may increase toxicity [16] , although acute and diffuse toxicity have been described recently by Chao et al. [26] after only 1 low-dose injection and by Aziz et al. [27] at doses lower than 30 µg. Although our study observed a higher rate of retinal toxicity than prior ocular oncology literature, our cohort is small, and, additionally, the variation in the determination of retinal toxicity limits any direct comparison with the clinical grading we utilized as proposed by Munier [14] . While prior studies reported "diffuse" or "widespread" RPE changes, our study reports greater than grade 3 toxicity. Nevertheless, while this new treatment protocol may reduce the frequency of EUAs, the higher rates of toxicity are a potential concern, and further research with a larger cohort of patients is required.
Our report describes a small series of patients treated for advanced retinoblastoma with vitreous seeding who received primary chemotherapy and concurrent IVM injections initiated with cycle 4 of chemotherapy. Our review demonstrates an overall globe salvage rate of 67%, which is comparable to the 68% salvage rate we reported for all patients treated with systemic chemotherapy and intravitreal chemotherapy [5] . More research and clinical experience is necessary to better define the best time to initiate intravitreal injections for vitreous seeding, as well as the optimal number and dosing schedule for IVM. The strategy of delivering concurrent IVM and systemic chemotherapy has the advantage of sparing children additional EUAs, although there did not appear to be an advantage for improving globe salvage rates in this small series. There was also an increased rate of ocular toxicity; however, the small size of the cohort limits any definitive conclusions. As ocular oncology centers continue to utilize this treatment for seeding, it is important to develop a consensus regarding the optimal way to integrate IVM into current chemotherapy regimens to optimize globe salvage results while minimizing associated toxicities.
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